MedImmune and Micromet Announce Initiation of Phase 1 Trial of the CEA BiTE Antibody MEDI-565

MedImmune, the global biologics unit of AstraZeneca PLC (NYSE:

) and Micromet, Inc. (NASDAQ:

) today announced the initiation of a Phase 1 trial of MEDI-565 (MT111) in patients with advanced gastrointestinal cancers. MEDI-565 is a BiTE antibody designed to direct a patient's T cells, the body's most potent killer cells, against cancer cells that express carcinoembryonic antigen.